7-Methyl-6,7,8,9,14,15-hexahydro-5H-benz[d]indolo[2,3-g]azecine: a new heterocyclic system and a new lead compound for dopamine receptor antagonists

J Med Chem. 2000 May 18;43(10):2079-81. doi: 10.1021/jm9911478.

Abstract

Partially hydrogenated derivatives of the new heterocyclic ring systems benz[d]indolo[2,3-g]azecine and bisindolo[3,2-d][2, 3-g]azecine were synthesized starting from lactones and amines via the described synthetic methods. In binding assays with rat striatal receptors, 7-methyl-6,7,8,9,14,15-hexahydro-5H-benz[d]indolo[2, 3-g]azecine (LE 300) proved to be of high affinity for the D(1) binding site (K(i) = 0.08 nmol for displacement of [(3)H]SCH23390), being superior in this assay to standards such as butaclamol and SCH23390. This compound was characterized as a dopamine antagonist by conditioned avoidance response test with mice. Thus, LE 300 represents the lead of a new class of dopamine antagonists for future investigations.

MeSH terms

  • Animals
  • Avoidance Learning / drug effects
  • Benzazepines / metabolism
  • Benzazepines / pharmacology
  • Binding, Competitive
  • Butaclamol / pharmacology
  • Corpus Striatum / metabolism
  • Dopamine Antagonists / chemical synthesis*
  • Dopamine Antagonists / metabolism
  • Dopamine Antagonists / pharmacology
  • Indoles / chemical synthesis*
  • Indoles / metabolism
  • Indoles / pharmacology
  • Mice
  • Molecular Conformation
  • Rats
  • Receptors, Dopamine D1 / metabolism
  • Swine

Substances

  • 7-methyl-6,7,8,9,14,15-hexahydro-5H-benz(d)indolo(2,3-g)azecine
  • Benzazepines
  • Dopamine Antagonists
  • Indoles
  • Receptors, Dopamine D1
  • Butaclamol